Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of “Buy” by Analysts
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been given an average recommendation of “Buy” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the […]
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been given an average recommendation of “Buy” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the […]
